About SaiOx™ + Hespiro™

Our Story

SaiOx, Inc. was founded in March of 2020 to help commercialize the Hespiro™ technology in order to provide relief to the 24 million people suffering from COPD in the United States.

The company, based in Tucson, Arizona, includes a team of executives with extensive experience bringing medical devices to market. Each team member is passionate about bringing this device to market.

Overview

Treatments for respiratory distress (COVID and COPD) are limited, uncomfortable, and have safety concerns. There are 93 million treatments per year for respiratory distress worldwide representing a $6 Billion market.
Hespiro™, SaiOx's patented device, provides a safe and effective non-invasive treatment for respiratory distress.
*Sources:World Health Organization (WHO), Centers for Disease Control (CDC),NationalInstitute of Health (NIH)

COVID-19 statistics as of 09:11 on September 10, 2020

Intellectual Property

The technology was developed by Dr. Sai Parthasarathy, who is the Chief of the Division of Pulmonary, Allergy, Critical Care and Sleep Medicine at Banner University Hospital in Tucson, AZ.

SaiOx™ is licensing the exclusive use of Dr. Parthasarathy’s original invention patent for the technology (US20160213879A1). Additionally, SaiOx™ has filed two other patents for other components of the device.”